Activation of alternative RTKs including Met mediates acquired resistance to targeted therapies in various types of cancers by maintaining the signaling of key downstream pathways.14 In our study, we examined the mechanisms underlying acquired resistance to an FGFR-TKIs and found Met overexpression in two different drug-resistant cell lines, only one of which had MET amplification. Here, MET is linked to cancer.